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ABSTRACT: Cystic fibrosis (CF) causes a relatively high medical consumption.
A large part of the treatment takes place at home. Because data regarding non-
hospital care are lacking, we wished to determine the costs of care of patients with
CF outside the hospital.
A questionnaire was sent to 73 patients with CF from two Dutch hospitals
(response rate 64%, 14 children and 33 adults). Average consumption and aver-
age costs per patient per year were calculated for children and adults for six cat-
egories: nonhospital medical care; domestic help; diet; travelling because of CF;
medication; and devices and special facilities at home, work or school.
The average nonhospital costs of care amounted to £4,641 per child per year
(range £712–13,269) and £10,242 per adult (range £1,653–26,571). Nonhospital med-
ical care for children and adults accounted for, respectively, 8 and 5% of these
costs, domestic help for 15 and 9%, diet for 10 and 7%, travelling because of CF for
4 and 8%, medication for 63 and 67%, and devices and special facilities at home,
work or school for 1 and 4%.
Nonhospital costs of care of cystic fibrosis are very high and amount to 50% of
the total (medical and nonmedical) lifetime costs of cystic fibrosis.
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Cystic fibrosis (CF) is the most frequent serious auto-
somal recessive disease in Caucasian populations. Char-
acteristics of CF are chronic bronchopulmonary infections,
pancreatic insufficiency, disturbances of the digestive
tract, and high sweat-sodium concentration. The birth
prevalence of CF in The Netherlands is 1 in 3,600 [1].
This means that in The Netherlands each year approx-
imately 50 children are born with CF. The total num-
ber of patients in The Netherlands is about 1,000.
The disease has a great impact on the length and qual-
ity of life and consumes a relatively high amount of
medical care. Treatment starts from the diagnosis and
continues throughout life, and consists of prescribing
additional calories and vitamins and fighting the respi-
ratory infections with antibiotics and intensive physio-
therapy. Care of patients with CF is not only intensive,
but demands support from relatives, friends, colleagues
etc and interferes with the normal daily life both of the
patient and relatives [2].
In a previous study, the costs of medical care in the
hospital were determined by reviewing the medical re-
cords of 81 patients (40 males and 41 females) of the
Beatrix Children's Clinic of the University Hospital
Groningen and the Leyenburg Hospital in The Hague
for the years 1990 and 1991 [3]. These hospital records
contain mainly information regarding medical treatment
and appointments, and lack data on medical costs out-
side the hospital, such as physiotherapy, visits to the
general practitioner and home medication, as well as the
costs of nonmedical (home) care, such as domestic help,
diet, travelling because of CF and special facilities. The
results of a questionnaire survey to determine these non-
hospital costs are described.
Patients and methods 
We developed a questionnaire containing items about
nonhospital medical care, domestic help, diet, travelling
because of CF, work/school, medication, and devices
and special facilities at home, work or school. Nonhos-
pital medical care was divided into care from general
practitioner, physiotherapist and homeopath/acupunc-
turist. The questionnaires were supplied with a number
so that a reminder could be sent if necessary; the list
with numbers and names was destroyed immediately after
the reminders were sent.
From the Beatrix Children's Clinic of the University
Hospital Groningen, 23 children were selected in such
a way that all age categories were represented. In the
Leyenburg Hospital, 50 adult nonterminal patients were
selected. These patients or their guardian (for children)
were asked to fill in the questionnaire on a daily basis
for 4 weeks in May 1993. The questionnaire was returned
by 14 Groningen patients (average age 10 yrs; range
1–17 yrs) and 33 Leyenburg patients with an average
age of 27 yrs (range 16–46 yrs) (table 1). The total
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response was, therefore, 64% (47 out of 73). Data from
one (adult) patient were not useful because this patient
lived abroad. For validation purposes, six responding
(parents of) patients, who had indicated they were will-
ing to have a telephone interview, were telephoned and
the questionnaire was talked through with them. It was
concluded that the questionnaires were filled in care-
fully and meticulously. Because the questionnaire was an-
onymous, it could not be linked to the patient's records;
therefore, it was not possible to stratify according to sever-
ity of disease.
The average consumption per patient was calculated
by dividing the total units consumed of that item by the
number of respondents. The average costs per patient
per year were calculated by multiplying the average con-
sumption by 13 (correction for a 4 weekly questionnaire
period) and multiplying this result with the unit costs.
If possible, unit costs were determined on the basis of
insurer allowances. If this was not possible, data from
the report "Cost calculation in health service research;
guidelines for practice" [4] were used. The source of
financing was not taken into account.
Results
The average consumption per item and the costs of
nonhospital care per year for children and adults with
CF are presented in tables 2 and 3, respectively. In these
tables, ranges of consumption and costs are also shown,
and the weighted average of the consumption and costs
for an "average" patient in The Netherlands, where 36%
of the patients are adult (aged ≥18 yrs) (J.M. Collée,
Dutch CF registration, personal communication).
General practitioner, physiotherapist and homeopath/acu-
puncturist 
One child (7%) and eight adults (25%) consulted their
general practitioner (GP) in the 4 weeks under study for
a total of one and nine consultations, respectively. It
was, therefore, estimated that a CF child has on aver-
age 0.9 GP consultations per year and an adult 3.7. At
a cost per consultation of £10.21, this amounted to £9
per child with CF per year and £37 per adult.
Six children (43%) and 14 adults (44%) indicated that
they had visited a physiotherapist for 4.7 and 5.9 times
per respondent per 4 weeks, respectively. This means
that a child with CF visited a physiotherapist on aver-
age 26 times a year and an adult 34 times. The corre-
sponding costs were £335 per year for children and £435
for adults, at a cost of £12.89 per consultation.
Five persons (one child and four adults) consulted a
homeopath or acupuncturist, of whom one patient had
four consultations and one had two. Average consulta-
tions per year were 0.9 for children and 3.3 for adults.
At a cost of £21.23 per consultation, this means that
consultations with a homeopath or acupuncturist cost
£20 per child per year and £69 per adult.
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Table 1.  –  Age distribution of responders
to questionnaire
Age Responders
yrs n
0–4 3
5–9 2
10–14 6
15–19 10
20–24 8
25–29 6
30–34 6
35+ 5
Total 46
Table 2.  –  Consumption of nonhospital care per year for patients with CF
Consumption per year
Children Adults Weighted average#
Nonhospital medical care consultations
General practitioner  n 0.9 (0–13) 3.7 (0–26) 1.9
Physiotherapist  n 26.0 (0–91) 33.7 (0–260) 28.8
Homeopath/acupuncturist  n 0.9 (0–13) 3.3 (0–52) 1.8
Domestic help  h 113 (0–1404) 148 (0–1248) 126
Diet items for CF  n 1.2 (0–3) 1.0 (0–3) 1.1
Travelling because of CF  km 857 (120–3192) 4194 (0–27774) 2058
Work, school, absence
Job contract  % total -      - 57     - -
Part-time  % employed -      - 41     - -
Absence  % contract hours 8 (0–65) 18 (0–25) -
Medication prescriptions  n 5.6 (1–8) 8.7 (4–16) 6.7
Pancreatic enzymes 1.1 (1–2) 0.8 (0–1) 1.0
Pulmonary medicines 1.3 (0–3) 3.6 (0–7) 2.1
Vitamins 2.1 (0–5) 1.7 (0–4) 1.9
Oral antibiotics 0.4 (0–2) 0.4 (0–1) 0.4
Parental antibiotics 0.1 (0–1) 0.3 (0–1) 0.2
Other medication 0.6 (0–2) 1.9 (0–5) 1.1
Devices and special facilities at home, work or school  % of patients
Nebulizer 43     - 88     - 59
Home trainer 21     - 69     - 38
Infusion pump 7     - 13     - 9
PEP-mask 43     - 16     - 33 
Special features 0     - 34     - 12
Other 21     - 31     - 25
Values are presented as average, and range in parenthesis. #:  per year for a Dutch CF patient.  CF:  cystic fibrosis;  PEP:  posi-
tive expiratory pressure.
Domestic help 
Fourteen adult patients (44%) responded that they had
domestic help for an average of 26 h during the 4 weeks.
This corresponds to almost 148 h·yr-1 per adult patient.
With standardized costs of £6.07 per hour, this amounts
to £897 per adult patient per year.
Caring for a child with CF costs the parents/guardians
a lot of extra time in comparison with a child without
CF; these costs were only taken into account if the par-
ents had some domestic help. Three parents of children
with CF (21%) received help from a caretaker or rela-
tive for 41 h on average during the 4 weeks which cor-
responds to 113 h domestic help and £687 per child per
year.
Diet for CF 
Diet used by patients with CF aims at ameliorating
the physical condition of the patient. Sixty-three percent
(29 out of 46) of all patients indicated that they used a
supplemental or special diet. Most patients used calo-
rie concentrates: Fortisip® (used by 16 patients); Poly-
cal® (12); Nutrison® (5); Nutrilon® (5); and Meritene
and Protifar (1 each). Furthermore, snacks such as Ever-
green®, Mars® and Nuts® were used by three patients,
and other products such as shakes (two patients) and
camomile tea, celery soup and cream (one patient each).
Average costs for a CF-specific diet amounted to £447
per year for children and £724 for adults.
Travelling because of CF 
Almost all respondents, 45 persons (98%) answered
that during the 4 weeks they had travelled once or more
because of CF, children on average 66 km and adults
333 km in the 4 weeks. This corresponded to 857 and
4,194 km per patient per year; costing £164 and £801
per year at £0.19 per km.
Work, school and absence 
Fifty-seven percent (17 persons) of the adult patients
reported that they held a contract of employment, of
which almost 50% had a part-time job. During the 4
weeks, five persons had been absent due to CF for a
total of 13 days (104 h), which was 18% of the total
contract hours of all 17 patients who had a contract (570
h). As a comparison, in the general population absence
due to sickness in The Netherlands in this period was
5.8% for males and 8.9% for females [5].
Three out of 18 patients (17%) who attended school
had been absent for one or more days; average absence
for these three patients in the 4 weeks was 9 days. This
means that a child with CF was on average absent from
school for 19.5 days per year. National data concerning
school absence are not known.
Medication 
All patients used medication for CF (children on aver-
age 5.6 different medicines and adults 8.7). For a bet-
ter overview, medication has been divided into six groups:
pancreatic enzymes (14 children and 25 adults); pul-
monary medicines (8 children and 29 adults); vitamins
(11 children and 25 adults); oral antibiotics (5 children
and 14 adults); parenteral antibiotics (2 children and 9
adults); and other medication (6 children and 25 adults).
The pancreatic enzymes were either pancrelipase (10
children and 23 adults) or pancreatin (5 children and 1
adult). Average costs per year amount to £1,434 for chil-
dren and £1,239 for adults.
In the pulmonary medicines group, many different
preparations were used. Salbutamol was used most fre-
quently in this group (3 children and 18 adults), fol-
lowed by colistin by nebulization (2 children and 17
adults), and acetylcysteine and ipratropium bromide (12
patients each). Other medicines were used less than 10
times. As mucolytic agent, mercaptoethanesulphonate
was recorded 13 times and acetylcysteine 12 times. On
average, 3.6 different prescriptions were taken by the
users of pulmonary medicines (children 2.3 and adults
3.9). Average costs amounted to £326 per year for chil-
dren and £2,035 for adults.
The vitamins A, B, C, D, E and K and multivitamins
were prescribed in different combinations. The average
costs per patient per year amounted to £114 for chil-
dren and £187 for adults.
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Table. 3.  –  Nonhospital costs of care in £ per year for a patient with cystic fibrosis (CF)
Costs per year  £
Children Adults Weighted
average#
Nonhospital medical care 364 (0–1173) 541 (0–3617) 428
Domestic help 687 (0–8517) 897 (0–7571) 763
Diet for CF 447 (0–1693) 724 (0–2632) 547
Travelling because of CF 164 (23–610) 801 (0–5307) 393
Pancreatic enzymes 1434 (292–3141) 1239 (0–2925) 1364
Pulmonary medicines 326 (0–1843) 2035 (0–9558) 941
Vitamins 114 (0–311) 187 (0–873) 140
Oral antibiotics 827 (0–8900) 1767 (0–4476) 1165
Parental antibiotics 145 (0–1042) 888 (0–17253) 413
Other medication 66 (0–291) 787 (0–4785) 326
Devices and special facilities at home, work or school 67 (0–266) 375 (0–2776) 178
Total nonhospital costs of care 4641 (712–13269) 10242 (1653–26571) 6657
Values are presented as average, and range in parenthesis.  #:  costs per year for Dutch CF patients. 
In the oral antibiotics group, eight different medicines
were indicated in the questionnaire. Of these, co-tri-
moxazole was used most frequently (1 child and 6 adults).
Two patients indicated that they used co-trimoxazole
for a fixed period of 8 months and 3 weeks, respec-
tively. The other patients did not indicate a fixed peri-
od of use. Ciproxin therapy was used by three patients
for an average of 3 weeks per patient. Average costs
for the oral antibiotics group were £827 per year for chil-
dren and £1,767 for adults.
In the parenteral antibiotics group, three different med-
icines were noted: flucloxacillin (2 children and 7 adults),
ceftazidime and tobramycin (both used by one adult).
Flucloxacillin therapy was used by two patients for 3
and 13 weeks, respectively. Ceftazidime was used as a
cure for 3 weeks. Average costs for the group parenteral
antibiotics were £145 per year for children and £888 for
adults.
In the "other medication" group, 31 users recorded 70
medicines; the most widely-used were insulin (7 adults,
no children), ranitidine and ursodeoxycholic acid (both
5 adults, no children). Four patients used two homeo-
pathic medicines on average. Average costs per patient
per year amounted to £66 for children and £787 for adults.
Devices and special facilities at home, work or school 
Three quarters of the respondents (6 children and 28
adults) used a nebulizer with (average) cost price of £475.
Using an (annuity) amortization scheme of 10 yrs and
an interest rate of 5%, this amounted to £26 per year
for children and £94 for adults. Almost a quarter of the
respondents (6 children and 5 adults) used a positive
expiratory pressure (PEP)-mask (cost price £73), aver-
age £9 per child per year and £3 per adult. For ame-
liorating or retaining the physical condition, 22 adult
respondents and 3 children used a home trainer and/or
rowing device (average cost price £235) or £3 per child
per year and £22 per adult, with an amortization scheme
of 10 yrs. Four adults used an infusion pump at home
(3 Cadd-plus and 1 Cadd-1), and one child used a Flo-
care device. Average costs for infusion pumps were £7
per child per year and £116 per adult. Other devices
were extra diapers (1), vibracan (1), ambulant oxygen
device (2), lung volume gauge (2) and air cleaner (1):
average costs per year £21 for children and £54 for
adults. Five persons (4 children and 1 adult) did not use
any device.
For eight (adult) respondents, a special facility at home
or at work had been made, e.g. a home trainer, shower
and oxygen at work, a personal (handicapped) parking
place and a shower-seat at home. The costs for an aver-
age adult patient with CF were £87 per year.
Average costs for devices and special facilities at
home, work or school consequently amounted to £67
per year for children and £375 per year for adult patients.
Discussion
The disease CF has a great impact on the daily life
of the patient and family. In this study, it was found
that the majority of patients had a special diet and 74%
sprayed with a nebulizer one or more times a day for
about 30 min. Almost all patients had medical care out-
side the hospital during the survey period: whereas 43%
had visited a physiotherapist, it can be assumed that the
other 26 patients performed exercises themselves. Total
nonhospital costs of CF care in The Netherlands amount-
ed to £4,641 per year for children and £10,242 for adults.
However, the costs of nonhospital care of children should
be considered with caution because data from only 14
children were collected.
This study is obviously most relevant to the Dutch
situation, but a significant part of it could be used to
assess costs for other (European) countries as well. Poss-
ible differences might be the rather low number of con-
sultations with a general practitioner (0.9 per year for
children and 3.3 for adults) and (reimbursed) visits to
a physiotherapist (26 times per year for children and 34
times for adults).
Caring for a family member or friend with CF takes
much time and energy. For example, almost half of the
adult patients had domestic help. These "direct costs"
were taken into account in this analysis. On the other
hand, caring for a child with CF takes more time for
parents/guardians than caring for a child without CF.
The use of these so-called "indirect costs", mainly pro-
duction losses, is disputed among economists. Therefore,
these costs of caring and of absence from work were
not included in the calculation.
CF is a disease for which tremendous progress is being
made in the field of medical care. Some developments
have already become reality since the time of our data
collection, such as recombinant human deoxyribonu-
clease (DNase) I to decrease the viscosity of purulent
airway secretions, and the increasing use of (heart-) lung
transplantations. Other developments have the possibil-
ity of progressing to the point of widespread clinical
use, such as gene therapy [6–9]. This progress in treat-
ment will obviously have an impact on the length and
quality of a patient's life, and will probably have a major
influence on the use and type of home care and, thus,
on the costs of nonhospital care. The results of the pre-
sent analysis should, therefore, be updated regularly.
The results of this analysis have been used in the cal-
culation of the total costs of the disease cystic fibrosis
[10]. For this reason, the medical consumption per age
category was determined and the nonhospital costs
added. These totals were discounted with a 5% interest
rate and were corrected for the survival curve (median
age 27 yrs) of the Dutch CF-registration [11], which
comprises 3,302 observed patient-years. In this way, the
so-called lifetime costs of CF were determined at £164,365,
of which £82,205 (=50%) were costs made outside the
hospital. Considering the cost-effectiveness of, for exam-
ple, continuous intravenous home treatment of airway
infections [12], the shift from hospital to extramural care
could eventually lead to lower costs of the disease. On
the other hand, an increase in the number of lung trans-
plantations is expected to occur, so that the future total
costs of care is difficult to predict.
The lifetime costs of CF have been used to prospec-
tively evaluate costs of screening for carriers of the CF
gene [13]. A choice for or against genetic screening on
the basis of economic motives is completely rejected by
the authors. Recently, a committee of the Dutch Health
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Council has formulated a set of reasonable criteria for
genetic screening programmes [14]. Cost aspects can
play a role in evaluating whether or not an otherwise
desirable screening programme can be organized, or that
costs of screening can be prohibitive. The results of our
costs study [13] indicate that costs are probably not pro-
hibitive for cystic fibrosis screening.
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